Abstract
No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
